Autopsy report · NCT02710669

New Formulations of Propafenone to Treat Atrial Fibrillation

“Study halted/terminated prematurely due to COVID.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 3 years 6 months before it stopped.
• 193 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Vanderbilt University

Sponsor type

University, hospital or other

Conditions

Atrial Fibrillation

Interventions

(R)-propafenone; (S)-Propafenone; Placebo

Participants

193

Sites

1

Countries

United States

Trials that died the same way

• Effects of E-Cigarette Power and Nicotine Content in Dual Users and Vapers
  “Study terminated due to COVID” (90% match in meaning)
• Effects of Community-center Based Dietary Intervention on Frailty Prevention and Regression in the Elderly.
  “Due to the impacts of COVID-19, the study had to terminate.” (87% match in meaning)
• Comparison of Efficacy of Behavioral Approaches for Treatment of Insomnia
  “Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention. COVID Complications.” (87% match in meaning)
• Acceptability, Feasibility and Safety of a Yoga Program for Chronic Pain in Sickle Cell Disease
  “Study terminated due to COVID-19 pandemic.” (86% match in meaning)
• RAman For Thyroid cancER
  “Covid19 halted study” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.